{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:55:17Z","timestamp":1781358917832,"version":"3.54.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gansu Provincial People's Hospital","award":["ZX-62000001-2022-254"],"award-info":[{"award-number":["ZX-62000001-2022-254"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:p>The prevalence of cardiovascular diseases has been rising globally, and various therapies have made significant strides in controlling the progression of these conditions and improving prognosis. Among these, pharmacological therapies have evolved rapidly and are increasingly integrated into clinical practice. Pharmacological treatments play a pivotal role in both basic research and clinical applications, particularly in deriving accurate conclusions from drug-related trials to address clinical challenges in drug selection and improve the cure rates of various diseases. L-type calcium channel blockers (LTCCBs) have attracted considerable research attention in recent years. With the accelerated development of novel drugs, the range of LTCCBs-based drug types has also diversified. This review aims to explore the relationship between LTCCBs and conditions such as hypertension, arrhythmias, ischemia\u2013reperfusion injury, and cardiomyopathy, with the goal of contributing to the diversification of treatment options for cardiovascular diseases patients. Additionally, it seeks to establish a theoretical foundation for future research and the clinical application of these therapies. It is imperative to conduct a thorough analysis and in-depth discussion regarding the deficiencies in the medication process as well as various application scenarios. With the advancement of science and the introduction of novel drugs into clinical practice, it is anticipated that these developments will play a critical guiding role in the diagnosis and treatment of complex clinical diseases.<\/jats:p>","DOI":"10.1097\/md.0000000000042799","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:01:16Z","timestamp":1750698076000},"page":"e42799","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances in research on the correlation between LTCCBs and cardiovascular diseases: A review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2379-9358","authenticated-orcid":false,"given":"Xiao","family":"Yang","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou City, Gansu Province, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5606-9053","authenticated-orcid":false,"given":"Xinghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gansu Provincial People\u2019s Hospital, Lanzhou City, Gansu Province, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260613","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium channel blockers: an update.","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am J Med"},{"key":"R2-20260613","first-page":"4","article-title":"Guideline on the assessment and management of cardiovascular risk in China.","volume":"34","year":"2019","journal-title":"Chin Circ J"},{"key":"R3-20260613","doi-asserted-by":"crossref","first-page":"e202012854","DOI":"10.1085\/jgp.202012854","article-title":"L-type channel inactivation balances the increased peak calcium current due to absence of Rad in cardiomyocytes.","volume":"153","author":"Ahern","year":"2021","journal-title":"J Gen Physiol"},{"key":"R4-20260613","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/CIRCRESAHA.123.322508","article-title":"Functional LTCC-\u03b2(2)AR complex needs Caveolin-3 and is disrupted in heart failure.","volume":"133","author":"Sanchez-Alonso","year":"2023","journal-title":"Circ Res"},{"key":"R5-20260613","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/0929867327666200714154059","article-title":"Advances in L-type calcium channel structures, functions and molecular modeling.","volume":"28","author":"Xu","year":"2021","journal-title":"Curr Med Chem"},{"key":"R6-20260613","doi-asserted-by":"crossref","first-page":"109336","DOI":"10.1016\/j.neuropharm.2022.109336","article-title":"L-type calcium channel regulation of dopamine activity in the ventral tegmental area to nucleus accumbens pathway: Implications for substance use, mood disorders and co-morbidities.","volume":"224","author":"Nunes","year":"2023","journal-title":"Neuropharmacology"},{"key":"R7-20260613","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pharmrev.120.000245","article-title":"L-type calcium channel blockers: a potential novel therapeutic approach to drug dependence.","volume":"73","author":"Little","year":"2021","journal-title":"Pharmacol Rev"},{"key":"R8-20260613","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1113\/JP276544","article-title":"Designer genetically encoded voltage-dependent calcium channel inhibitors inspired by RGK GTPases.","volume":"598","author":"Colecraft","year":"2020","journal-title":"J Physiol"},{"key":"R9-20260613","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1038\/s41467-022-35025-7","article-title":"Selective posttranslational inhibition of Ca(V)\u03b2(1)-associated voltage-dependent calcium channels with a functionalized nanobody.","volume":"13","author":"Morgenstern","year":"2022","journal-title":"Nat Commun"},{"key":"R10-20260613","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1570159X17666190927113021","article-title":"Nimodipine Reappraised: an Old Drug With a Future.","volume":"18","author":"Carlson","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"R11-20260613","doi-asserted-by":"crossref","first-page":"647021","DOI":"10.3389\/fphar.2021.647021","article-title":"The HCN channel blocker ZD7288 induces emesis in the least shrew (Cryptotis parva).","volume":"12","author":"Zhong","year":"2021","journal-title":"Front Pharmacol"},{"key":"R12-20260613","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12916-021-02165-4","article-title":"Different hypertension thresholds and cognitive decline: a pooled analysis of three ageing cohorts.","volume":"19","author":"Ma","year":"2021","journal-title":"BMC Med"},{"key":"R13-20260613","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.arcmed.2018.11.005","article-title":"New challenges for hypertension treatment.","volume":"49","author":"Rosas-Peralta","year":"2018","journal-title":"Arch Med Res"},{"key":"R14-20260613","first-page":"3715","article-title":"Epidemiology and management of hypertension in China: an analysis using data from the annual report on cardiovascular health and diseases in China (2021).","volume":"25","author":"Ma","year":"2022","journal-title":"Chin Gen Pract"},{"key":"R15-20260613","doi-asserted-by":"crossref","first-page":"e0284364","DOI":"10.1371\/journal.pone.0284364","article-title":"L-type calcium channel blocker increases VEGF concentrations in retinal cells and human serum.","volume":"18","author":"Kumar","year":"2023","journal-title":"PLoS One"},{"key":"R16-20260613","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/pharmaceutics13040527","article-title":"Use of pluronic surfactants in gel formulations of photosensitive 1,4-dihydropyridine derivatives: a potential approach in the treatment of neuropathic pain.","volume":"13","author":"Ioele","year":"2021","journal-title":"Pharmaceutics"},{"key":"R17-20260613","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/anie.202011793","article-title":"Structural basis of the modulation of the voltage-gated calcium ion channel Ca(v) 1.1 by dihydropyridine compounds.","volume":"60","author":"Gao","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"R18-20260613","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2019.04.043","article-title":"Molecular basis for ligand modulation of a mammalian voltage-gated Ca(2+) channel.","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"R19-20260613","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/10641963.2018.1445753","article-title":"The effect of an L\/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients.","volume":"41","author":"Ito","year":"2019","journal-title":"Clin Exp Hypertens"},{"key":"R20-20260613","doi-asserted-by":"crossref","first-page":"119043","DOI":"10.1016\/j.lfs.2021.119043","article-title":"Azelnidipine treatment reduces the expression of Ca(v)1.2 protein.","volume":"269","author":"Nasu","year":"2021","journal-title":"Life Sci"},{"key":"R21-20260613","doi-asserted-by":"crossref","first-page":"172873","DOI":"10.1016\/j.ejphar.2019.172873","article-title":"Hydroxysafflor yellow A actives BK(Ca) channels and inhibits L-type Ca channels to induce vascular relaxation.","volume":"870","author":"Wang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R22-20260613","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.pharep.2019.05.009","article-title":"GABA(A) receptor, K(ATP) channel and L-type Ca(2+) channel is associated with facilitation effect of H(2)S on the baroreceptor reflex in spontaneous hypertensive rats.","volume":"71","author":"Teng","year":"2019","journal-title":"Pharmacol Rep"},{"key":"R23-20260613","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2019.09.052","article-title":"Angiotensin-(1-12)\/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen.","volume":"297","author":"Reyes","year":"2019","journal-title":"Int J Cardiol"},{"key":"R24-20260613","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3390\/nu12061782","article-title":"Aqueous fraction from hibiscus sabdariffa relaxes mesenteric arteries of normotensive and hypertensive rats through calcium current reduction and possibly potassium channels modulation.","volume":"12","author":"Alsayed","year":"2020","journal-title":"Nutrients"},{"key":"R25-20260613","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ijbiomac.2020.05.100","article-title":"The inhibition effect of uncarialin A on voltage-dependent L-type calcium channel subunit alpha-1C: inhibition potential and molecular stimulation.","volume":"159","author":"Yun","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"R26-20260613","doi-asserted-by":"crossref","first-page":"17369","DOI":"10.1073\/pnas.2007598117","article-title":"L-type Ca(2+) channel blockers promote vascular remodeling through activation of STIM proteins.","volume":"117","author":"Johnson","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"R27-20260613","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.yjmcc.2021.01.005","article-title":"Rad-GTPase contributes to heart rate via L-type calcium channel regulation.","volume":"154","author":"Levitan","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"R28-20260613","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41431-020-00784-8","article-title":"Atrial fibrillation-a complex polygenetic disease.","volume":"29","author":"Andersen","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"R29-20260613","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yjmcc.2022.08.001","article-title":"Elucidating the role of the L-type calcium channel in excitability and energetics in the heart: the ISHR 2020 Research Achievement Award Lecture.","volume":"172","author":"Hool","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"R30-20260613","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12012-020-09597-z","article-title":"Isoliensinine eliminates afterdepolarizations through inhibiting late sodium current and L-Type calcium current.","volume":"21","author":"Liu","year":"2021","journal-title":"Cardiovasc Toxicol"},{"key":"R31-20260613","doi-asserted-by":"crossref","first-page":"e202012584","DOI":"10.1085\/jgp.202012584","article-title":"Suppression of ventricular arrhythmias by targeting late L-type Ca2+ current.","volume":"153","author":"Angelini","year":"2021","journal-title":"J Gen Physiol"},{"key":"R32-20260613","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7861\/clinmed.cme.20.1.3","article-title":"Supraventricular tachycardia: an overview of diagnosis and management.","volume":"20","author":"Kotadia","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"R33-20260613","doi-asserted-by":"crossref","first-page":"e010915","DOI":"10.1161\/CIRCEP.122.010915","article-title":"First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301).","volume":"15","author":"Stambler","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R34-20260613","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ehjcvp\/pvz038","article-title":"Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries.","volume":"6","author":"Eroglu","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R35-20260613","doi-asserted-by":"crossref","first-page":"220","DOI":"10.24272\/j.issn.2095-8137.2020.042","article-title":"The pathological role of ferroptosis in ischemia\/reperfusion-related injury.","volume":"41","author":"Yan","year":"2020","journal-title":"Zool Res"},{"key":"R36-20260613","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1021\/acsbiomaterials.0c01197","article-title":"Ischemia reperfusion injury: opportunities for nanoparticles.","volume":"6","author":"Zang","year":"2020","journal-title":"ACS Biomater Sci Eng"},{"key":"R37-20260613","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/biom12111625","article-title":"Pyroptosis: a newly discovered therapeutic target for ischemia-reperfusion injury.","volume":"12","author":"Zheng","year":"2022","journal-title":"Biomolecules"},{"key":"R38-20260613","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/1440-1681.13329","article-title":"Comparison of effects of L\/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.","volume":"47","author":"Naseratun","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R39-20260613","doi-asserted-by":"crossref","first-page":"112432","DOI":"10.1016\/j.biopha.2021.112432","article-title":"Calenduloside E protects against myocardial ischemia-reperfusion injury induced calcium overload by enhancing autophagy and inhibiting L-type Ca(2+) channels through BAG3.","volume":"145","author":"Wang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R40-20260613","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12272-020-01261-y","article-title":"Protective effect of quercetin against myocardial ischemia as a Ca(2+) channel inhibitor: involvement of inhibiting contractility and Ca(2+) influx via L-type Ca(2+) channels.","volume":"43","author":"Liang","year":"2020","journal-title":"Arch Pharm Res"},{"key":"R41-20260613","doi-asserted-by":"crossref","first-page":"174194","DOI":"10.1016\/j.ejphar.2021.174194","article-title":"Andrographolide protects against isoproterenol-induced myocardial infarction in rats through inhibition of L-type Ca(2+) and increase of cardiac transient outward K(+) currents.","volume":"906","author":"Elasoru","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R42-20260613","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","article-title":"Classification, epidemiology, and global burden of cardiomyopathies.","volume":"121","author":"McKenna","year":"2017","journal-title":"Circ Res"},{"key":"R43-20260613","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.3390\/ijms222212522","article-title":"Recent findings related to cardiomyopathy and genetics.","volume":"22","author":"Yamada","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R44-20260613","doi-asserted-by":"crossref","first-page":"9850","DOI":"10.1038\/s41598-019-46367-6","article-title":"Blockade of L-type Ca(2+) channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-\u03baB pathway.","volume":"9","author":"Ikeda","year":"2019","journal-title":"Sci Rep"},{"key":"R45-20260613","doi-asserted-by":"crossref","first-page":"e002460","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes.","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"R46-20260613","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.118.034549","article-title":"Chronic calmodulin-kinase II activation drives disease progression in mutation-specific hypertrophic cardiomyopathy.","volume":"139","author":"Lehman","year":"2019","journal-title":"Circulation"},{"key":"R47-20260613","first-page":"1","article-title":"Guidelines for rational use of drugs in coronary heart disease (2nd edition).","volume":"10","year":"2018","journal-title":"Chin J Front Med Sci"},{"key":"R48-20260613","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate \u2013 a meta-analysis of randomized trials.","volume":"29","author":"Makani","year":"2011","journal-title":"J Hypertens"},{"key":"R49-20260613","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.107.133892","article-title":"The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.","volume":"325","author":"Major","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R50-20260613","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.","volume":"124","author":"Makani","year":"2011","journal-title":"Am J Med"},{"key":"R51-20260613","doi-asserted-by":"crossref","first-page":"e1918425","DOI":"10.1001\/jamanetworkopen.2019.18425","article-title":"Magnitude of and characteristics associated with the treatment of calcium channel blocker-induced lower-extremity edema with loop diuretics.","volume":"2","author":"Vouri","year":"2019","journal-title":"JAMA Network Open"},{"key":"R52-20260613","first-page":"220","article-title":"Expert recommendations on the application of non-dihydropyridine calcium channel blockers in cardiovascular diseases.","volume":"23","author":"Sun","year":"2015","journal-title":"Chin J Hypertens"},{"key":"R53-20260613","first-page":"28","article-title":"Guidelines for Rational Drug Use in Hypertension (2nd Edition).","volume":"9","year":"2017","journal-title":"Chin J Front Med Sci"},{"key":"R54-20260613","first-page":"2501","article-title":"Multidisciplinary expert consensus on heart rate management for hypertensive patients in China (2021 Edition).","volume":"24","author":"Shi","year":"2021","journal-title":"Chin Gen Pract"},{"key":"R55-20260613","first-page":"188","article-title":"Analysis of common adverse drug reactions and rational drug use in patients with hypertension.","volume":"18","author":"Peng","year":"2021","journal-title":"J North Pharm"},{"key":"R56-20260613","first-page":"1","article-title":"Guidelines for rational drug use in heart failure (2nd edition).","volume":"11","year":"2019","journal-title":"Chin J Front Med Sci"},{"key":"R57-20260613","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/1060028018779082","article-title":"A review of ACE inhibitors and ARBs in black patients with hypertension.","volume":"52","author":"Helmer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"R58-20260613","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/hr.2014.169","article-title":"Systolic hypertension: an increasing clinical challenge in Asia.","volume":"38","author":"Park","year":"2015","journal-title":"Hypertens Res"},{"key":"R59-20260613","first-page":"635","article-title":"Efficacy of calcium channel blockers on major cardiovascular outcomes for the treatment of hypertension in Asian populations: a meta-analysis.","volume":"33","author":"Tran","year":"2017","journal-title":"Can J Cardiol"},{"key":"R60-20260613","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of Randomized Controlled Trials.","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"R61-20260613","first-page":"428","article-title":"Research progress on the efficacy and safety of calcium channel blockers in treating chronic kidney disease complicated with hypertension.","volume":"28","author":"Xia","year":"2017","journal-title":"China Pharmacy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:01:30Z","timestamp":1781355690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":61,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042799","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}